Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Maria Goutsou"'
Autor:
Maria Goutsou, Angela M. Amend Kwasnik, Ozgecan Uluscu, Robert Stianchi, Gillian M. Cannon, Paul M. Peloso
Publikováno v:
Journal of Medical Marketing: Device, Diagnostic and Pharmaceutical Marketing. 13:74-81
We describe patterns of treatment of rheumatoid arthritis with biologics in the United States during 2000–2010 using longitudinal data in the IMS LifeLink™ health plan claims database. Rheumatoid arthritis prevalent and incident cases were identi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5dbf46740a1923ef71123de38cc79e7d
https://doi.org/10.1177/1745790413480520
https://doi.org/10.1177/1745790413480520
Autor:
Mark R. Green, James E. Herndon, Alan P. Lyss, Kathleen J. Propert, Kristine Mason-Coughlin, Michael C. Perry, Maria Goutsou
Publikováno v:
American Journal of Clinical Oncology. 15:399-404
From April 2 to July 9, 1989, Cancer and Leukemia Group B (CALGB) conducted a Phase II study of etoposide and carboplatin in advanced (AJC Stage IIIb-IV) non-small-cell lung cancer (NSCLC) patients whose performance status (PS) was 0-2. The combinati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f42296665bc3b000e2bce30e75941a79
https://doi.org/10.1097/00000421-199210000-00003
https://doi.org/10.1097/00000421-199210000-00003
Autor:
L H Maurer, Michael C. Perry, Arthur T. Skarin, Robert W. Carey, Joseph Aisner, R Cooper, R Slawson, P Chahinian, Maria Goutsou, Mark R. Green
Publikováno v:
Journal of Clinical Oncology. 10:1230-1236
PURPOSE In prior Cancer and Leukemia Group B (CALGB) studies, combined chemotherapy and thoracic irradiation was superior to chemotherapy alone in limited-disease (LD) small-cell lung cancer (SCLC). A combined modality pilot study was performed to te
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1037a62e38509f09125ded9ee4b7555d
https://doi.org/10.1200/jco.1992.10.8.1230
https://doi.org/10.1200/jco.1992.10.8.1230
Publikováno v:
Cancer Investigation. 10:215-219
Eighty-six eligible patients with non-small cell lung cancer were treated on a Phase II, CALGB study with high-dose, 24-h continuous intravenous 5-fluorouracil every 2 weeks. Objective responses were seen in 7 (8%) patients with 1 (1%) complete respo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a020a54c753790cdea00ac19c1a04e2c
https://doi.org/10.3109/07357909209032763
https://doi.org/10.3109/07357909209032763
Autor:
Maria Goutsou, Frederick Richards, David J. Perry, Vera Hirsh, A. Philippe Chahinian, Caron Modeas, Vishram B. Rege, Elaine A. Muchmore, Bernard J. Poiesz, Mark R. Green
Publikováno v:
Cancer. 67:2974-2979
Two hundred forty-seven patients with previously untreated nonresectable non-small cell lung cancer (NSCLC) were entered in a prospective, randomized Phase II trial. Response assessment was possible in 232 patients, and 237 patients were evaluable fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bfe24ab33dd103f6830de5d777ce0ca5
https://doi.org/10.1002/1097-0142(19910615)67:12<2974::aid-cncr2820671206>3.0.co
https://doi.org/10.1002/1097-0142(19910615)67:12<2974::aid-cncr2820671206>3.0.co
Autor:
Jacob D. Bitran, Stephen L. Graziano, Caron Modeas, Maria Goutsou, J. Ellerton, James E. Herndon, Michael C. Perry, Mark R. Green, Donald C. Doll
Publikováno v:
Cancer chemotherapy and pharmacology. 29(1)
Between July 2, 1987, and August 21, 1987, Cancer and Leukemia Group B (CALGB) conducted a phase II evaluation of carboplatin (CBDCA) and vinblastine (VBL) in advanced non-small-cell lung cancer. Of the 58 patients who entered the study, 55 were elig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af3893926429d4d6f43b68ea9c5bb770
https://pubmed.ncbi.nlm.nih.gov/1660354
https://pubmed.ncbi.nlm.nih.gov/1660354
Autor:
Caron Modeas, Mary E. Costanza, Mark R. Green, Maria Goutsou, Stephen L. Graziano, Harvey Kreisman
Publikováno v:
European journal of cancer (Oxford, England : 1990). 26(10)
The response to cisplatin in non-small cell lung cancer (NSCLC) is limited by the renal and neurological toxicities of this agent. Carboplatin has modest activity in NSCLC and when given in conventional doses has a different spectrum of toxicity. Bot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::114af34582169179a87a9ff4b2b3a448
https://pubmed.ncbi.nlm.nih.gov/2177346
https://pubmed.ncbi.nlm.nih.gov/2177346
Autor:
K M Coughlin, Joseph M. Corson, Mark R. Green, M. R. Cooper, Yasunosuke Suzuki, Stephen L. Graziano, Nicholas J. Vogelzang, Joseph Aisner, Maria Goutsou
Publikováno v:
Cancer chemotherapy and pharmacology. 27(3)
Carboplatin (400 mg/m2) was given at 28-day intervals to 41 patients with malignant mesothelioma. In all, 40 patients were eligible and evaluable for response. Partial responses were seen in 2 cases (5%); regression of evaluable disease, in 1 patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d75da054b5fc583784409ab38f3ad5c
https://pubmed.ncbi.nlm.nih.gov/2265461
https://pubmed.ncbi.nlm.nih.gov/2265461